Latest carfilzomib Stories
Maximum tolerated dose (MTD) identified and expansion cohort open to enrollment; Minimal Response (MR) or better has been observed in 25% of 8 patients treated to date at the MTD or higher
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
SAN FRANCISCO, Dec.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
- Final results from binimetinib Phase 2 in NRAS melanoma confirmed prior Progression Free Survival result and demonstrated encouraging Overall Survival- BOULDER, Colo., Nov.
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc.
- a meat pie that is usually eaten at Christmas in Quebec